– USA, CA – NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced the nomination of Dr. Roger Perlmutter, M.D., Ph.D., to stand for election to the board of directors at its June 8, 2021, AGM.
“As a luminary in our industry, Roger has an extensive track record leading highly productive teams translating breakthrough science into impactful medicines that treat grievous disease. Given the broad range of Roger’s drug discovery and development expertise, we are honored that Roger has agreed to join the NGM board. His recent experience developing Keytruda is an especially powerful match with NGM’s emerging oncology portfolio,” said Executive Chairman, Bill Rieflin.
“A true scientific pioneer, Roger’s insights and extensive experience bringing powerful medicines from bench to bedside are ideal for NGM’s biology-driven approach and our mission to deliver life-changing medicines,” said CEO, Dr. David Woodhouse. “We are thrilled with Roger’s nomination and look forward to his many contributions as we advance our diverse clinical pipeline in the liver and metabolic diseases, retinal diseases, and oncology and continue to operate our highly productive discovery research engine.”
The company also announced that Dr. David Schnell and Mac Tichenor who have served on the Board of Directors are resigning from the Board of Directors, effective upon the expiration of their respective terms at the 2021 AGM.
Bill Rieflin commented: “On behalf of our Board, I’d also like to thank David and Mac for their decade of devoted service and intellectual contributions to NGM’s evolution.”
About Dr. Perlmutter
Dr. Perlmutter brings a wealth of expertise in drug discovery and development as a highly accomplished biopharma industry leader and academic with over 35 years of experience. Dr. Perlmutter is currently Chairman of Merck Research Laboratories, and for the previous, nearly eight years was executive vice president of Merck & Co. and president of Merck Research Laboratories. While at Merck, Dr. Perlmutter played a pivotal role in the approval and development of numerous life-saving medicines and, in particular, was responsible for the development of KEYTRUDA (pembrolizumab), Merck’s breakthrough anti-PD-1 therapy. Before Merck, Dr. Perlmutter was executive vice president and head of research and development at Amgen, where he was responsible for the registration of novel therapeutics in the areas of oncology, endocrinology, hematology, inflammation, and osteoporosis, including Sensipar, Prolia, and XGEVA.
“I have dedicated my professional career to developing medicines that improve and extend life, and NGM is fundamentally driven by the same motivation,” said Dr. Perlmutter. “In particular, I have long admired Dr. Jin-Long Chen, with whom I was privileged to work at Amgen, and I am impressed by the way that his ability to elucidate important new biological principles through careful experimentation has enabled NGM to develop a broad pipeline of innovative therapeutic candidates. As a future member of NGM’s board, I look forward to helping to advance NGM’s mission: to deliver transformative medicines to patients.”
Dr. Perlmutter has served as a director on numerous corporate boards in the U.S. and Europe and currently serves on the Board of insitro, a privately held machine learning-driven drug discovery and development company.
Before assuming leadership roles in the biopharmaceutical industry, Dr. Perlmutter was a professor in the Departments of Immunology, Biochemistry, and Medicine at the University of Washington, Seattle, and also served as Chairman of its Department of Immunology, where he was at the same time an investigator of the Howard Hughes Medical Institute. Dr. Perlmutter was also previously both a Distinguished Fellow and past president of the American Association of Immunologists and is a Fellow of the American Academy of Arts and Sciences and the American Association for the Advancement of Science. Dr. Perlmutter graduated from Reed College in 1973 and received his M.D. and Ph.D. degrees from Washington University in St. Louis in 1979.
About NGM Biopharmaceuticals, Inc.
NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on a scientific understanding of key biological pathways underlying liver and metabolic diseases, retinal diseases, and oncology. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs in clinical development.
For more information: https://www.ngmbio.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.